Recent News

• 03.31.2026 - Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
• 03.31.2026 - Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
• 03.03.2026 - Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 03.03.2026 - Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 02.24.2026 - Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
• 02.24.2026 - Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

Recent Filings

• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.03.2026 - EX-99.1 EX-99.1
• 03.03.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.03.2026 - 8-K Current report
• 02.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2026 - 144 Report of proposed sale of securities
• 02.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2026 - 4 Statement of changes in beneficial ownership of securities